Enzymatica AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0003943620
SEK
2.50
0.11 (4.6%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Stille AB
Devyser Diagnostics AB
Enzymatica AB
Paxman AB
Senzime AB
Mentice AB
Integrum AB
BrainCool AB
C-RAD AB
Doxa AB
SyntheticMR AB

Why is Enzymatica AB ?

1
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -46.35%, its profits have risen by 5.3%
2
Underperformed the market in the last 1 year
  • Even though the market (OMX Stockholm 30) has generated returns of 10.97% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -46.35% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Enzymatica AB for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Enzymatica AB
-46.35%
-0.10
60.48%
OMX Stockholm 30
10.97%
0.59
18.59%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-13.49%
EBIT Growth (5y)
-214.88%
EBIT to Interest (avg)
-30.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.38
Tax Ratio
0.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.61
EV to EBIT
-8.89
EV to EBITDA
-8.89
EV to Capital Employed
4.76
EV to Sales
9.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-53.50%
ROE (Latest)
-36.86%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
NET PROFIT(HY)

Higher at SEK -19.43 MM

ROCE(HY)

Highest at -34.53%

NET SALES(Q)

Highest at SEK 18.33 MM

-1What is not working for the Company
RAW MATERIAL COST(Y)

Grown by 10.58% (YoY

Here's what is working for Enzymatica AB

Net Profit
Higher at SEK -19.43 MM
than preceding 12 month period ended Dec 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (SEK MM)

Net Sales
Highest at SEK 18.33 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (SEK MM)

Net Sales
At SEK 18.33 MM has Grown at 39.08%
over average net sales of the previous four periods of SEK 13.18 MM
MOJO Watch
Near term sales trend is positive

Net Sales (SEK MM)

Here's what is not working for Enzymatica AB

Raw Material Cost
Grown by 10.58% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales